Skip to main content
. 2022 Oct 22;37(11):2277–2289. doi: 10.1007/s00384-022-04265-w

Fig. 2.

Fig. 2

Risk of adverse outcomes in COVID-19 patients with IBD versus comparative population. The comparison population includes the control population infected with SARS-CoV-2 adjusted for age, gender, and comorbidities and the general population infected with SARS-CoV-2 during the same period